KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Assets (2018 - 2026)

Castle Biosciences' Assets history spans 8 years, with the latest figure at $578.6 million for Q4 2025.

  • On a quarterly basis, Assets rose 8.91% to $578.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $578.6 million, a 8.91% increase, with the full-year FY2025 number at $578.6 million, up 8.91% from a year prior.
  • Assets hit $578.6 million in Q4 2025 for Castle Biosciences, up from $562.8 million in the prior quarter.
  • Over the last five years, Assets for CSTL hit a ceiling of $578.6 million in Q4 2025 and a floor of $425.4 million in Q2 2023.
  • Historically, Assets has averaged $474.9 million across 5 years, with a median of $458.1 million in 2022.
  • Biggest five-year swings in Assets: soared 263.66% in 2021 and later fell 7.19% in 2023.
  • Tracing CSTL's Assets over 5 years: stood at $462.6 million in 2021, then fell by 3.3% to $447.3 million in 2022, then increased by 1.34% to $453.3 million in 2023, then grew by 17.18% to $531.2 million in 2024, then grew by 8.91% to $578.6 million in 2025.
  • Business Quant data shows Assets for CSTL at $578.6 million in Q4 2025, $562.8 million in Q3 2025, and $544.7 million in Q2 2025.